News Related to B-cell Mediated Autoimmune Diseases

Related coverage linked through entity extraction aliases.

Vertex expands beyond cystic fibrosis with CASGEVY Germany deal and WuXi pact

May 10, 2026

Vertex secured a Germany reimbursement agreement for CASGEVY and signed a WuXi Biologics pact for a preclinical autoimmune T-cell engager. The moves add to efforts to build revenue beyond cystic fibrosis.

iPSC-derived NK cell pipeline shows 12-plus active players and 15-plus drugs

Apr 24, 2026

The iPSC-derived NK cells pipeline includes 12+ active players and 15+ drugs in development. FT522 is in Phase I, while CNTY-101 and NCR300 are among other programs in the clinic.